Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]

on behalf of the VERTIS CV Investigators

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
StateAccepted/In press - 2022


  • Body weight
  • Chronic kidney disease
  • Ertugliflozin
  • Estimated glomerular filtration rate
  • Kidney outcomes
  • Sodium–glucose cotransporter 2 inhibitor

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this